Register entry
Catalent Indiana, LLC
- Registered sites
- 1
- Drug products
- 27
- Live patents
- 0
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingActive ingredient (API) manufactureLabellingFinished drug manufacturePackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Catalent Indiana, LLC | Bloomington, INUnited States | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3005949964 |
Catalogue
Marketed products
27Showing 27 of 27.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| - | Aflibercept | INJECTION, SOLUTION | EXPORT ONLY |
| - | Benralizumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Cemiplimab | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | Diluent | SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Durvalumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Epinephrine | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | Epinephrine | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | Imetelstat sodium | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | Odronextamab | INJECTION, SOLUTION | EXPORT ONLY |
| - | Odronextamab | INJECTION, SOLUTION | EXPORT ONLY |
| - | adalimumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | aflibercept | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | ansuvimab-zykl | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | ansuvimab-zykl | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | atoltivimab, maftivimab, and odesivimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | durvalumab injection, solution | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | eteplirsen | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | eteplirsen | INJECTION | DRUG FOR FURTHER PROCESSING |
| - | nivolumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | pozelimab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | rHuPH20 | INJECTION | BULK INGREDIENT |
| - | ravulizumab | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | semaglutide | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
| - | semaglutide | INJECTION, SOLUTION | DRUG FOR FURTHER PROCESSING |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.